Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: A meta-analysis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gong, Jianfeng ^a   Zhu, Lijing ^a   Guo, Zhen ^a   Li, Yi ^a   Zhu, Weiming ^a   Li, Ning ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL TUMOR; DISEASE DURATION; DYSPLASIA; ENTERITIS; HUMAN; META ANALYSIS; RISK REDUCTION; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT INDICATION; ULCERATIVE COLITIS; CHEMICALLY INDUCED; INFLAMMATORY BOWEL DISEASES; RISK;

6-MERCAPTOPURINE; AZATHIOPRINE; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK;

EID: 84896723109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081487     Document Type: Article

References (48)

1. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535. doi:10.1136/gut.48.4.526. PubMed: 11247898. (Pubitemid 32234798)
2. Itzkowitz SH, Yio X (2004) Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287: G7-G17. doi:10.1152/ajpgi.00079.2004. PubMed: 15194558. (Pubitemid 38802113)
3. Levine JS, Burakoff R (2007) Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.Inflamm Bowel Dis 13: 1293-1298. doi:10.1002/ibd.20186. PubMed: 17567870. (Pubitemid 47597780)
4. Nguyen GC, Gulamhusein A, Bernstein CN (2012) 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 107: 1298-1304. doi:10.1038/ajg.2012.198. PubMed: 22751467.
5. Chande N, Tsoulis DJ, Macdonald JK (2013) Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 4:CD000545.
6. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK (2012) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 9:CD000478. PubMed: 2297204617253451.
7. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.Gut 54: 1121-1125. doi:10.1136/gut.2004. 049460. PubMed: 16009685. (Pubitemid 41025906)
8. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB et al. (2011) Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141: 1621-1628. doi:10.1053/j.gastro.2011.06.050. PubMed: 21708105.
9. Dasari BV, McBrearty A, Gardiner K (2012) Immunosuppression in patients with Crohn's disease and neoplasia: an ongoing clinical dilemma. Dis Colon Rectum 55: 1008-1011. doi:10.1097/DCR.0b013e31825d9269. PubMed: 22874610.
10. Devlin SM (2012) Do thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease or is this an unanswerable question? Inflamm Bowel Dis 18: 1184-1185. doi: 10.1002/ibd.21869. PubMed: 22271441.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE). Group - JAMA 283: 2008-2012. doi:10.1001/jama.283.15.2008.
12. Wells GA, Shea B, O'Connell D, Peterson J, Welch V et al. (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Avaiable at Available: http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp (Accessed 7 April)
13. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH et al. (2012) A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator- treated adult patients with inflammatory bowel disease. Am J Gastroenterol 107: 1051-1063. doi: 10.1038/ajg.2012.89. PubMed: 22613901.
14. Armstrong RG, West J, Card TR (2010) Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 105: 1604-1609. doi:10.1038/ajg.2009.745. PubMed: 20104215.
15. Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E et al. (2012) Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis 6: 578-587. doi:10.1016/j.crohns.2011.11.005. PubMed: 22398047.
16. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC et al. (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 106: 319-328. doi:10.1038/ajg.2010.428. PubMed: 21045815.
17. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T et al. (2006) Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 12: 205-211. doi:10.1097/01.MIB.0000217770.21261.ce. PubMed: 16534422.
18. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A (1997) The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112: 29-32. doi: 10.1016/S0016-5085(97) 70215-4. PubMed: 8978339. (Pubitemid 27008982)
19. Nieminen U, Jussila A, Nordling S, Mustonen H, Färkkilä MA (2014) Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case-control observational study based on registry data. Int J Cancer 2014;134: 189-196 PubMed: 23797639.
20. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, et al. (2013) Inflammation is an Independent Risk Factor for Colonic Neoplasia in Patients with Ulcerative Colitis: a Case-Control Study. Clin Gastroenterol Hepatol. 2013 Jul 17pii: S1542-3565(13)01035-510.1016/j.cgh. [Epub ahead of print].
21. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459. doi:10.1053/j.gastro.2003.11.010. PubMed: 14762782. (Pubitemid 38182302)
22. Tang J, Sharif O, Pai C, Silverman AL (2010) Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 55: 1696-1703. doi:10.1007/s10620-009-0942-x. PubMed: 19705280.
23. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB et al. (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134: 89-95. doi: 10.7326/0003-4819-134-2-200101160-00008. PubMed: 11177311. (Pubitemid 32096335)
24. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J et al. (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 130: 1941-1949. doi:10.1053/j.gastro.2006.03.028. PubMed: 16762617. (Pubitemid 43816957)
25. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T et al. (2013) Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients with Inflammatory Bowel Disease. Gastroenterology;145: 166-175. doi:10.1053/j.gastro.2013.03.044. PubMed: 23541909.
26. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK et al. (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343: 1249-1252. doi:10.1016/S0140-6736(94)92150-4. PubMed: 7910274. (Pubitemid 24158045)
27. Fraser AG, Orchard TR, Robinson EM, Jewell DP (2002) Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16: 1225-1232. doi:10.1046/j.1365-2036.2002.01297.x. PubMed: 12144571.
28. Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E (2013) Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. World J Gastroenterol 19: 4877-4886. doi:10.3748/wjg.v19.i30.4877. PubMed: 23946592.
29. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S et al. (2007) Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133: 1099-1105. doi:10.1053/j.gastro.2007.08.001. PubMed: 17919486. (Pubitemid 47494461)
30. Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C et al. (2005) Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 3: 1015-1021. doi: 10.1016/S1542-3565(05)00738-X. PubMed: 16234048. (Pubitemid 41415750)
31. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A (2013) Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease. Am J Epidemiol 177: 1296-1305. doi:10.1093/aje/kws375. PubMed: 23514635.
32. Satchi M, Korelitz BI, Panagopoulos G, Bratcher J, Yu C et al. (2013) Is treatment with 6-mercaptopurine for colitis associated with the development of colorectal cancer? Inflamm Bowel Dis 19: 785-788. doi: 10.1097/MIB. 0b013e318289664c. PubMed: 23392347.
33. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD et al. (2012) Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 61: 235-240. doi:10.1136/gut.2011.237412. PubMed: 21602529.
34. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G et al. (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27: 385-389. doi:10.1111/j.1440-1746.2011. 06865.x. PubMed: 21793904.
35. Arber N, Levin B (2008) Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 134: 1224-1237. doi:10.1053/j.gastro.2008.02.012. PubMed: 18395100. (Pubitemid 351451998)
36. Subramanian V, Logan RF (2011) Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 25: 593-606. doi:10.1016/j.bpg.2011.09.003. PubMed: 22122774.
37. Mason M, Siegel CA (2013) Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 19: 1306-1321. PubMed: 23470503.
38. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535. doi: 10.1136/gut.48.4.526. PubMed: 11247898. (Pubitemid 32234798)
39. Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10: 639-645. doi:10.1016/j.cgh.2012.01.010. PubMed: 22289873.
40. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233. doi:10.1056/NEJM199011013231802. PubMed: 2215606. (Pubitemid 20366527)
41. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A et al. (2001) Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120: 1356-1362. doi:10.1053/gast.2001.24052. PubMed: 11313305. (Pubitemid 32322309)
42. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF (2011) Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 34: 497-508. doi:10.1111/j.1365-2036.2011.04753.x. PubMed: 21692821.
43. Rutter M, Saunders B, Wilkinson K et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459. doi:10.1053/j.gastro.2003.11.010. PubMed: 14762782. (Pubitemid 38182302)
44. Lutgens L, [!(surname)!], van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD et al. (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19: 789-799. doi:10.1097/MIB.0b013e31828029c0. PubMed: 23448792.
45. Karlén P, Kornfeld D, Broström O, Löfberg R, Persson PG et al. (1998) Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42: 711-714. doi:10.1136/gut.42.5.711. PubMed: 9659169. (Pubitemid 28261062)
46. Teichgräber U, Atreya I, Atreya R, Schwab M, Neurath MF (2013) Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis 19: E54-E55. doi: 10.1097/01.MIB. 0000438750.97521.d4. PubMed: 22532373.
47. Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, et al. (2013) The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.J Crohns Colitis. Aug 6. PubMed: 23932783 pii: S1873-9946(13)00242-0 10.1016/j.crohns [Epub ahead of print]. PubMed: 23932783.
48. Dyson JK, Rutter MD (2012) Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol; 18: 3839-3848. doi:10.3748/wjg.v18.i29.3839. PubMed: 22876036.